Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Raised to “Hold” at Zacks Research

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued on Monday,Zacks.com reports.

Several other brokerages also recently weighed in on FMS. Citigroup reaffirmed a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Friday, April 24th. Morgan Stanley restated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Wednesday, May 6th. Wall Street Zen downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Weiss Ratings lowered shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, May 7th. Finally, Jefferies Financial Group raised shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “moderate sell” rating in a research note on Friday, May 8th. Five research analysts have rated the stock with a Hold rating and four have given a Sell rating to the company. According to MarketBeat.com, Fresenius Medical Care AG & Co. KGaA presently has a consensus rating of “Reduce” and a consensus target price of $28.00.

Fresenius Medical Care AG & Co. KGaA Trading Up 2.5%

Shares of Fresenius Medical Care AG & Co. KGaA stock opened at $24.20 on Monday. The firm has a 50-day simple moving average of $22.38 and a two-hundred day simple moving average of $22.84. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.86 and a current ratio of 1.20. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $20.02 and a fifty-two week high of $27.76. The company has a market cap of $13.00 billion, a P/E ratio of 12.73, a price-to-earnings-growth ratio of 4.26 and a beta of 0.78.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $1.05 earnings per share for the quarter. The firm had revenue of $5.34 billion during the quarter. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.90% and a net margin of 4.88%. As a group, equities analysts predict that Fresenius Medical Care AG & Co. KGaA will post 2.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA

A number of institutional investors and hedge funds have recently bought and sold shares of FMS. Brooklyn Investment Group grew its stake in Fresenius Medical Care AG & Co. KGaA by 5.4% during the 4th quarter. Brooklyn Investment Group now owns 8,860 shares of the company’s stock valued at $212,000 after acquiring an additional 450 shares in the last quarter. Advisors Preferred LLC lifted its stake in Fresenius Medical Care AG & Co. KGaA by 6.1% in the 1st quarter. Advisors Preferred LLC now owns 10,226 shares of the company’s stock worth $231,000 after purchasing an additional 589 shares in the last quarter. Hantz Financial Services Inc. boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 10.5% during the 4th quarter. Hantz Financial Services Inc. now owns 7,370 shares of the company’s stock worth $176,000 after purchasing an additional 699 shares during the last quarter. Fifth Third Bancorp grew its position in shares of Fresenius Medical Care AG & Co. KGaA by 4.0% in the fourth quarter. Fifth Third Bancorp now owns 18,766 shares of the company’s stock valued at $447,000 after purchasing an additional 726 shares in the last quarter. Finally, Arax Advisory Partners increased its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 121.6% in the fourth quarter. Arax Advisory Partners now owns 1,613 shares of the company’s stock valued at $38,000 after purchasing an additional 885 shares during the last quarter. 8.37% of the stock is currently owned by institutional investors and hedge funds.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.